The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective
Open accessAbstract
Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
From Ionic Currents to Molecular Mechanisms
Catterall, W. A. (2000) · Neuron · doi:10.1016/s0896-6273(00)81133-2 · Cited by 2,118
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
From magic bullets to designed multiple ligands
Morphy, R., Kay, C., & Rankovic, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 729
Structure-based maximal affinity model predicts small-molecule druggability
Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C., & Huang, E. S. (2007) · Nature Biotechnology · doi:10.1038/nbt1273 · Cited by 695
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Giordano, S., & Petrelli, A. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783503212 · Cited by 457
Challenges and opportunities of drug repositioning
Novac, N. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.004 · Cited by 374
Multi-target approach for natural products in inflammation
Koeberle, A., & Werz, O. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.006 · Cited by 317
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240
Applications of Connectivity Map in drug discovery and development
Qu, X. A., & Rajpal, D. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.017 · Cited by 235
Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases
Li, K., Schurig-Briccio, L. A., Feng, X., Upadhyay, A., Pujari, V., Lechartier, B., Fontes, F. L., Yang, H., Rao, G., Zhu, W., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500131s · Cited by 223
Xie, L., Xie, L., Kinnings, S. L., & Bourne, P. E. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134630 · Cited by 202
Amiodarone Has Intrinsic Anti-Trypanosoma cruzi Activity and Acts Synergistically with Posaconazole
Benaim, G., Sanders, J. M., Garcia-Marchán, Y., Colina, C., Lira, R., Caldera, A. R., Payares, G., Sanoja, C., Burgos, J. M., Leon-Rossell, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050691f · Cited by 185
Combination Therapy in Epilepsy: When and What to Use
Kwan, P., & Brodie, M. J. (2006) · Drugs · doi:10.2165/00003495-200666140-00004 · Cited by 183
Multitarget approach for natural products in inflammation
Jude, S., & Gopi, S. (2021) · Inflammation and Natural Products · doi:10.1016/b978-0-12-819218-4.00004-3 · Cited by 174
Simone Tranches Dias, K., & Viegas, C. (2014) · Current Neuropharmacology · doi:10.2174/1570159x1203140511153200 · Cited by 173
In-Silico Approaches to Multi-target Drug Discovery
Xiao, H., Shi, Z., Tan, C., Jiang, Y., Go, M., Low, B. C., & Chen, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0065-2 · Cited by 144
Antiepileptic drug therapy: Does mechanism of action matter?
Brodie, M. J., Covanis, A., Gil‐Nagel, A., Lerche, H., Perucca, E., Sills, G. J., & White, H. S. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.05.025 · Cited by 134
From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy
Zheng, H., Fridkin, M., & Youdim, M. B. H. (2014) · Pharmaceuticals · doi:10.3390/ph7020113 · Cited by 121
Rationally Designed Multitarget Agents Against Inflammation and Pain
Hwang, S. H., Wecksler, A. T., Wagner, K. M., & Hammock, B. D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130013 · Cited by 111
Bosetti, F., Weerasinghe, G. R., Rosenberger, T. A., & Rapoport, S. I. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01701.x · Cited by 110
Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam
Kaminski, R. M., Matagne, A., Patsalos, P. N., & Klitgaard, H. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01713.x · Cited by 103
Ghelardoni, S., Tomita, Y. A., Bell, J. M., Rapoport, S. I., & Bosetti, F. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.05.012 · Cited by 95
Multitarget drugs: the present and the future of cancer therapy
Petrelli, A., & Valabrega, G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902781907 · Cited by 93
Millan, M. J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001496 · Cited by 83
Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease
Youdim, M. B. H., Kupershmidt, L., Amit, T., & Weinreb, O. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70032-4 · Cited by 82
Rational Polytherapy with Antiepileptic Drugs
Lee, J. W., & Dworetzky, B. A. (2010) · Pharmaceuticals · doi:10.3390/ph3082362 · Cited by 74
Speck‐Planche, A., & Cordeiro, M. N. D. S. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1006195 · Cited by 59
Bianchi, M. T., Pathmanathan, J. S., & Cash, S. S. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.09.049 · Cited by 59
Metabolic control analysis to identify optimal drug targets
Hornberg, J. J., Bruggeman, F. J., Bakker, B. M., & Westerhoff, H. V. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-7567-6_7 · Cited by 58
Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery
Strebhardt, K., Becker, S., & Matthess, Y. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.962510 · Cited by 53
Systems biology, complexity, and the impact on antiepileptic drug discovery
Margineanu, D. G. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.08.029 · Cited by 43
CNS Drug Development – Lost in Translation?
Talevi, A., Bellera, C. L., Ianni, M., Gantner, M. E., Bruno‐Blanch, L. E., & Castro (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712802762356 · Cited by 36
Self-citationWong, E. H. F., Nikam, S. S., & Shahid, M. (2008) · PubMed · Cited by 34
Vertical Pathway Targeting in Cancer Therapy
Shahbazian, D., Sznol, J. A., & Kluger, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00001-4 · Cited by 17
Talevi, A., & Bruno‐Blanch, L. E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6464-8_14 · Cited by 16
Self-citation
Cited by
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Melatonin receptors: molecular pharmacology and signalling in the context of system bias
Cecon, E., Oishi, A., & Jockers, R. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13950 · Cited by 281
Gunter, N. V., Teh, S. S., Lim, Y. M., & Mah, S. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.594202 · Cited by 91
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88
Stevenson, G. A., Kirshner, D., Bennion, B. J., Yang, Y., Zhang, X., Zemla, A., Torres, M. W., Epstein, A., Jones, D., Kim, H., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00722 · Cited by 7
Metadata
- Authors
- Talevi, A.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2015-09-22
- Volume
- 6
- Pages
- 205-205
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W1808513053
- Cited by
- 381
- References
- 44
- FWCI
- 15.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.